Canada markets closed

Fennec Pharmaceuticals Inc. (FENC)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.75-0.05 (-0.86%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close5.80
Open5.86
Bid3.75 x 1000
Ask5.80 x 1000
Day's Range5.68 - 5.93
52 Week Range3.82 - 10.08
Volume13,505
Avg. Volume35,728
Market Cap149.727M
Beta (5Y Monthly)-0.07
PE Ratio (TTM)N/A
EPS (TTM)-0.63
Earnings DateAug 08, 2022 - Aug 12, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.20
  • GlobeNewswire

    Fennec Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Business Update

    ~ FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~ ~ If Approved by the FDA, PEDMARKTM Stands to Be the First Therapy for the Prevention of Cisplatin-Induced Hearing Loss in Children ~ ~ Company Has Approximately $18.3 Million in Cash and $5 Million of Funded Debt ~ RESEARCH TRIANGLE PARK, N.C., May 12, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM

  • Zacks

    Can Adherex Technologies Inc. (FENC) Climb 92% to Reach the Level Wall Street Analysts Expect?

    The average of price targets set by Wall Street analysts indicates a potential upside of 91.9% in Adherex Technologies Inc. (FENC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  • GlobeNewswire

    Fennec Pharmaceuticals Announces FDA Acceptance for Filing of New Drug Application Resubmission for PEDMARK™

    ~ Prescription Drug User Fee Act (PDUFA) target action date set for September 23, 2022 ~RESEARCH TRIANGLE PARK, N.C., , April 27, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company’s resubmitted New Drug Application (NDA) for PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicit